XSTOBIOWKS
Market cap5mUSD
Dec 23, Last price
0.80SEK
1D
-3.61%
1Q
-17.92%
IPO
-92.10%
Name
Bio-Works Technologies AB
Chart & Performance
P/E
—
P/S
1.42
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.34%
Rev. gr., 5y
46.24%
Revenues
44m
+6.23%
Net income
-57m
L+26.41%
CFO
-59m
L+47.92%
Earnings
Feb 21, 2025
Profile
Bio-Works Technologies AB (publ), a biotechnology company, researches, develops, manufactures, and supplies agarose-based separation products to purify proteins, peptides, and other biomolecules primarily in Sweden. It offers activated and affinity resins; BabyBio columns; immobilized metal-ion affinity chromatography resins; ion exchange resins; OptioBio glass columns; screening kits; and size exclusion chromatography resins. The company's products are used in antibodies, his-tagged proteins, proteins, peptides, oligonucleotides, and viruses and vaccines applications. Bio-Works Technologies AB (publ) founded in 2006 and is headquartered in Uppsala, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 43,896 6.23% | 41,320 88.59% | 21,910 202.88% | ||||||
Cost of revenue | 17,075 | 12,473 | 31,932 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | 26,821 | 28,847 | (10,022) | ||||||
NOPBT Margin | 61.10% | 69.81% | |||||||
Operating Taxes | 2,087 | 255 | 3,572 | ||||||
Tax Rate | 7.78% | 0.88% | |||||||
NOPAT | 24,734 | 28,592 | (13,594) | ||||||
Net income | (56,821) 26.41% | (44,950) 247.32% | (12,942) -70.95% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 33,652 | 4,038 | 86,668 | ||||||
BB yield | -13.12% | -0.55% | -10.10% | ||||||
| Debt | |||||||||
Debt current | (10,373) | (1,931) | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 6,797 | ||||||||
Net debt | (39,382) | (76,248) | (104,676) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (58,990) | (39,880) | (13,369) | ||||||
CAPEX | (860) | (1,124) | (942) | ||||||
Cash from investing activities | (860) | (1,124) | (942) | ||||||
Cash from financing activities | 33,263 | 4,038 | 83,962 | ||||||
FCF | 22,272 | 29,992 | (13,299) | ||||||
| Balance | |||||||||
Cash | 39,382 | 65,875 | 102,745 | ||||||
Long term investments | |||||||||
Excess cash | 37,187 | 63,809 | 101,650 | ||||||
Stockholders' equity | (301,860) | (245,322) | (200,496) | ||||||
Invested Capital | 345,893 | 302,641 | 307,021 | ||||||
ROIC | 7.63% | 9.38% | |||||||
ROCE | 60.91% | 50.33% | |||||||
| EV | |||||||||
Common stock shares outstanding | 36,113 | 35,006 | 31,206 | ||||||
Price | 7.10 -66.19% | 21.00 -23.64% | 27.50 202.20% | ||||||
Market cap | 256,404 -65.12% | 735,120 -14.34% | 858,176 210.05% | ||||||
EV | 217,022 | 658,872 | 753,500 | ||||||
EBITDA | 27,432 | 29,322 | (9,265) | ||||||
EV/EBITDA | 7.91 | 22.47 | |||||||
Interest | 3 | 23 | 18 | ||||||
Interest/NOPBT | 0.01% | 0.08% | |||||||